EBR 3.06% 95.0¢ ebr systems inc.

General Investor Information EBR Systems, page-66

  1. 4,722 Posts.
    lightbulb Created with Sketch. 1855
    "Even if there's a little pullback tomorrow, the momentum has certainly changed."

    Yes it's been quite refreshing the last few days, on solid volume which may could attract bigger investors who generally stay away from the smaller more illiquid stocks.

    It's hard to know whether it will pullback in coming days, or continue to consolidate at current levels while the stale IPO holders, who were in the red, reduce or fully exit the stock, or even advance.

    IMO, based on my very conservative valuation, the current share price still remains at a significant discount.

    For those that are yet to seek registration to the Company’s monthly newsletter I copy part of the CEO's message sent to registered shareholders today:-
    "Dear Investors,
    "We are proud to announce that EBR Systems has met its primary safety and efficacy endpoints in its pivotal SOLVE-CRT trial of the WiSE Cardiac Resynchronization Therapy (CRT) System.
    "This is the most significant milestone in our company’s history and an important step forward in our path towards our Premarket Approval application to the FDA, achieving regulatory approvals, and commencing our commercialisation strategy.
    "There is a huge global unmet need for our wireless pacing technology. We are proud to provide state-of-the art technology to our physicians who have implanted the WiSE CRT System in over 450 patients around the world so far and enabled significant improvement in the condition of their patients, most who had failed conventional treatment.
    "EBR Systems estimates an addressable market of US$2.5 billion for WiSE, initially targeting patients who cannot receive CRT from existing devices or are at high risk from conventional upgrades.
    "Pending regulatory approvals, EBR Systems intends to initially go to market in the US, Australia, and major European countries.
    "There is an expansion opportunity up to US$7.1 billion as the WiSE technology platform can be potentially expanded into other patient groups, indications, and geographies in the future. Pending regulatory approvals, EBR Systems intends to initially go to market in the US, Australia, and major European countries.

    Also he provided a link to an interview after the presentation at the HRS Conference:-
    https://manacommunications.us21.list-manage.com/track/click?u=2ca297326b7706f1b1d5eba3e&id=59cbbb2323&e=2bc543fd67
    Last edited by longreach: 23/05/23
 
watchlist Created with Sketch. Add EBR (ASX) to my watchlist
(20min delay)
Last
95.0¢
Change
-0.030(3.06%)
Mkt cap ! $292.7M
Open High Low Value Volume
98.0¢ 98.5¢ 94.5¢ $213.8K 222.8K

Buyers (Bids)

No. Vol. Price($)
1 3956 94.5¢
 

Sellers (Offers)

Price($) Vol. No.
95.0¢ 151 3
View Market Depth
Last trade - 16.10pm 13/09/2024 (20 minute delay) ?
EBR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.